VIARTIS

 

 

 PARKINSON'S DISEASE NEWS

 

 

 

 

 

29th November 2012 - News release

PIMAVANSERIN CLINICAL TRIAL RESULTS

Arcadia have disclosed the results of their Phase III clinical trial of Pimavanserin, which is being developed by Arcadia for the treatment of  Parkinson's Disease Psychosis. Parkinson's Disease Psychosis usually consists of visual hallucinations and delusions in addition to the usual Parkinson's Disease symptoms. Pimavanserin is an antagonist of serotonin 5-HT2A receptors.  For more information go to Pimavanserin.

In the clinical trial patients took either 40 mg of Pimavanserin or a placebo once a day for six weeks. Patients also received stable doses of their existing Parkinsonís Disease treatments throughout the study. Those people taking Pimavanserin reduced their score on the SAPS-PD scale by 5.79. Those people taking a placebo reduced their score by 2.73. Although the results were described as "representing a highly significant and clinically meaningful treatment" the effects of Pimavanserin were quite moderate when compared to those taking a placebo. Half the effect of Pimavanserin was achieved by effectively taking nothing at all. The study also fails to assess the long term effects of Pimavanserin as it lasted only 43 days. All drugs, due to a process called "feedback inhibition" end up reducing their over time. The most common adverse events were urinary tract infection and falls, but these were at a rate very little more than for those taking a placebo.  Most symptoms of psychosis in Parkinson's Disease are due to Parkinson's Disease drugs themselves. For more information go to the News release. For a printable version of this article click here. For more news go to Parkinson's Disease News.

 

E-MAIL NOTIFICATION : If you would like to be notified by e-mail when any new articles are added to Parkinson's Disease News,  please merely e-mail [email protected] with the message "subscribe".  No form of identity is required.  E-mail addresses are not used for any other purpose.

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Parkinson's Disease News details all significant new research, news reports, new books, and new resources concerning Parkinson's Disease and those medical disorders that often coincide with Parkinson's Disease. It is compiled from an analysis of  all newly published research, news reports, new clinical trials, all newly published books, and new web sites. A summary and analysis of the new research are provided,  as well as links to the complete abstracts and news reports

                                    

 

 
©2006-2012  Viartis
 
2015-08-29 19:23:31
 
[email protected]